A new analysis suggests a familiar class of diabetes drugs might offer a powerful benefit for people with a serious and progressive heart condition. The review looked at over 7,000 patients with transthyretin amyloid cardiomyopathy (ATTR-CM), a disease where abnormal proteins stiffen the heart muscle. All patients were already on standard disease-modifying therapy, and researchers compared those who also took an SGLT2 inhibitor to those who did not.
The findings were striking. Taking an SGLT2 inhibitor was strongly associated with a lower risk of death from any cause and from cardiovascular problems specifically. It was also linked to a lower risk of major heart events like heart attack or stroke, and even a small improvement in a key measure of kidney function. The analysis did not find a significant effect on hospitalizations for heart failure.
It's crucial to understand what this does and doesn't mean. This is a meta-analysis of observational studies, which can show a link but cannot prove the drug caused the better outcomes. The results are promising, but they come with the inherent biases of this type of research. The authors themselves stress that high-quality randomized controlled trials are needed to confirm these findings and establish true cause and effect.